FOR IMMEDIATE RELEASE

Caris Life Sciences Announces Presentation of Comprehensive Tumor Profiling Research at 2015 Society of Gynecologic Oncology (SGO) Annual Meeting

Research Demonstrates Clinical Utility of Caris Molecular Intelligence to Inform Therapeutic Strategies in Rare and Aggressive Women’s Cancers

Irving, Tex., Mar. 23, 2015 – Caris Life Sciences® today announced the acceptance of 10 key clinical studies by the Society of Gynecological Oncology for presentation at the 2015 Annual Meeting on Women’s Cancers to be held March 28 through March 31 in Chicago, Ill. All 10 studies, which analyze a variety of rare, aggressive and refractory women’s cancers, utilized Caris Molecular Intelligence™, the company’s panomic, comprehensive tumor profiling service, which provides oncologists with unique molecular information about their patients’ tumors to better inform treatment decisions.

The collective set of studies conducted in collaboration with researchers from leading academic and clinical institutions, such as New York Presbyterian/Columbia University Medical Center and Cleveland Clinic, will significantly advance the molecular understanding of cancer in a wide range of tumor types including cervical, uterine, endometrial and ovarian malignancies. Of the 10 accepted abstracts, one was awarded an oral presentation in a focused plenary session and one was awarded featured poster status and will be presented in a Meet-the-Professor session where researchers will be available for questions. The study abstracts are embargoed until the start of their respective sessions in which they are presented.

“Gynecological cancers pose unique treatment challenges, especially in rare and refractory diseases where little therapeutic guidance exists beyond the standard, first-line treatment option,” noted Sandeep K. Reddy, M.D., Chief Medical Officer at Caris Life Sciences. “We are very excited about the data to be presented at the annual meeting of the Society for Gynecological Oncology which demonstrates how multiplatform molecular profiling has advanced our understanding of these cancers and can inform difficult treatment decisions, potentially leading to better outcomes for patients.”

Notable Caris Life Sciences datasets include:

• **Saturday, March 28, 5:30–6:30 PM, Salon C, Featured Posters I: Meet the Professor Reception: Connecting Minds for a Better Future.** Abstract #3999: “Molecular characterization of 361 cases of uterine carcinomas reveal alterations in the DNA repair and PI3K pathways as potential therapeutic targets,” presented by Nathaniel L. Jones, M.D., NYP/Columbia University of Medicine.

Additional Caris Life Sciences datasets utilizing Caris Molecular Intelligence include:

• **Saturday, March 28, 9:55 AM–6:30 PM, Exhibit Hall, Poster Session A**

• **Sunday, March 29, 7:00 AM–4:00 PM, Exhibit Hall, Poster Session B**


  Abstract #4520: “Biomarker comparison of epithelial ovarian cancer and endometrial cancer by multiplatform tumor profiling,” presented by Haider Mahdi, M.D., Cleveland Clinic.

  Abstract #3988: “Molecular profile of uterine papillary serous carcinoma compared to ovarian serous carcinoma: Is it the same disease at different site?” presented by Haider Mahdi, M.D., Cleveland Clinic.


  Abstract #3911: “Paving the Road to Personalized Medicine in Cervical Cancer: Theranostic Biomarker Evaluation in a 592-Specimen Library,” presented by Rebecca Feldman, Ph.D., Caris Life Sciences.

  Abstract #3886: “Microarray analysis of vascular endothelial growth factor (VEGF)-dependent angiogenic biomarkers in squamous cell carcinoma (SCCA) and adenocarcinoma of the cervix,” presented by presented by Rebecca Feldman, Ph.D., Caris Life Sciences.

---

**About Caris Life Sciences® and Caris Molecular Intelligence™**

Caris Life Sciences® is a leading biosciences company focused on fulfilling the promise of precision medicine through quality and innovation. Caris Molecular Intelligence™, one of the industry’s leading tumor profiling services with more than 70,000 patients profiled, provides oncologists with the most potentially clinically actionable treatment options available to personalize cancer care today. Using a variety of advanced profiling technologies to assess relevant biological changes in each patient’s tumor, Caris Molecular Intelligence connects biomarker data generated from a tumor with biomarker-drug associations supported by evidence in the relevant clinical literature. The company is also developing Carisome® TOP™ technology, a revolutionary and proprietary blood-based profiling platform for
diagnosis, prognosis, and theranosis of cancer and other complex diseases. Headquartered in Irving, Texas, Caris Life Sciences offers services throughout Europe, the U.S., Australia and other international markets. To learn more, please visit www.CarisLifeSciences.com.

###

**Media Inquiries**
David Patti
JFK Communications
dpatti@jfkhealth.com
(609) 241-7365